Anthem Biosciences Limited (ANTHEM) Financial Results — Revenue ₹4,182 Cr

1 Financial Results 🔴 High Importance Neutral 📄 PDF

Revenue: ₹4,182 CrNet Profit: ₹1,199 Cr

📢 Key Event
Anthem Biosciences released Q1FY27 unaudited consolidated financial results

🔄 What Changed
Revenue declined 22.6% YoY to ₹4,182 Mn; PAT margin improved to 27.1%; EBITDA margin expanded to 39.6%

🔮 What's Next
Management expects sustained revenue growth and margin improvement through cost efficiencies and yield optimization in H2FY27

💡 Investor Takeaway
Revenue decline reflects delivery timing shifts, but margin expansion and strong underlying demand support long-term growth prospects

Anthem Biosciences reported consolidated revenue of ₹4,182 Mn for Q1FY27, down 22.6% YoY, with EBITDA at ₹1,755 Mn (39.6% margin) and PAT at ₹1,199 Mn (27.1% margin). CRDMO revenue was ₹3,408 Mn, Specialty Ingredients ₹774 Mn, and Other Income ₹249 Mn. PAT declined 11.7% YoY but improved from prior quarter. The company highlighted timing shifts in customer deliveries and sustained demand, with management targeting margin expansion through cost efficiencies and yield optimization. Forward-looking statements were included in the release.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

📢 Key Event
Anthem Biosciences released Q1FY27 earnings presentation on July 21, 2026

🔄 What Changed
Revenue declined 22.6% YoY to ₹4,182 crores; EBITDA margin expanded 153 bps to 39.6%

🔮 What's Next
Management expects sustained revenue growth aligned with historical performance and improved margins through cost efficiencies

💡 Investor Takeaway
Revenue decline is offset by margin expansion and strong cash position, indicating operational resilience

Anthem Biosciences reported consolidated revenue of ₹4,182 crores for Q1FY27, down 22.6% YoY, with EBITDA at ₹1,755 crores and PAT at ₹1,199 crores. EBITDA margin improved to 39.6% from 38.1% YoY, while PAT margin stood at 27.1%. Net cash position was ₹17,197 crores as of June 30, 2026. The company highlighted strong demand and margin discipline despite revenue headwinds.

3 Financial Results 🔴 High Importance Neutral 📄 PDF

Revenue: ₹4,182 CrNet Profit: ₹1,199 Cr

📢 Key Event
Anthem revises Q1FY27 press release with updated financials

🔄 What Changed
Revised revenue down 22.6% YoY to ₹4,182 Mn; PAT margin at 27.1%

🔮 What's Next
Board approved results; earnings call scheduled for July 22, 2026 at 11:30 am IST

💡 Investor Takeaway
Revenue decline reflects timing shifts in customer deliveries, but margins remain strong and growth is expected in H2.

Anthem Biosciences reported Q1FY27 consolidated revenue of ₹4,182 Mn, down 22.6% YoY, with EBITDA at ₹1,755 Mn (39.6% margin) and PAT at ₹1,199 Mn (27.1% margin). The company highlighted CRDMO revenue of ₹3,408 Mn and specialty ingredients at ₹774 Mn, while noting other income of ₹249 Mn and a PAT margin improvement from prior quarters.

📊 Stock Analysis — ANTHEM ✨ Ask AI About This